188 related articles for article (PubMed ID: 12824197)
1. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
Pressman Lovinger S
JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
[No Abstract] [Full Text] [Related]
2. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of biologics in early rheumatoid arthritis.
Finckh A; Bansback N; Liang MH
Ann Intern Med; 2010 Mar; 152(5):333-4; author reply 334. PubMed ID: 20194244
[No Abstract] [Full Text] [Related]
4. Drugs for rheumatoid arthritis.
Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?
Boers M
Ann Intern Med; 2009 Nov; 151(9):668-9. PubMed ID: 19884628
[No Abstract] [Full Text] [Related]
6. When is switching warranted among biologic therapies in rheumatoid arthritis?
Reynolds A; Koenig AS; Bananis E; Singh A
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
[TBL] [Abstract][Full Text] [Related]
7. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Dougados M; Emery P; Gibofsky A; Kavanaugh AF; Keystone EC; Klareskog L; Russell AS; van de Putte LB; Weisman MH
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii2-9. PubMed ID: 14532138
[No Abstract] [Full Text] [Related]
8. Management of rheumatoid arthritis.
Handa R
Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis and tuberculosis in the tumor necrosis factor inhibitors era: observations from Brazil.
da Rocha Castelar Pinheiro G
J Clin Rheumatol; 2005 Dec; 11(6):344-6. PubMed ID: 16371812
[No Abstract] [Full Text] [Related]
10. The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
Bansback NJ; Young A; Brennan A
Rheumatology (Oxford); 2005 Jan; 44(1):3-4. PubMed ID: 15328422
[No Abstract] [Full Text] [Related]
11. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
[No Abstract] [Full Text] [Related]
13. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
Nurmohamed MT; Dijkmans BA
Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
[TBL] [Abstract][Full Text] [Related]
14. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
Yen JH
Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.
Rajakulendran S; Gadsby K; Allen D; O'Reilly S; Deighton C
Ann Rheum Dis; 2006 Dec; 65(12):1678-9. PubMed ID: 17105865
[No Abstract] [Full Text] [Related]
16. Perioperative management of biologic agents used in treatment of rheumatoid arthritis.
Mushtaq S; Goodman SM; Scanzello CR
Am J Ther; 2011 Sep; 18(5):426-34. PubMed ID: 20216205
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
Finucane KA; Archer CB
Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
[No Abstract] [Full Text] [Related]
18. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Hochman D; Wolff B
JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
[No Abstract] [Full Text] [Related]
19. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Callegari PE; Schaible TF; Boscia JA
JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
[No Abstract] [Full Text] [Related]
20. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Costenbader KH; Glass R; Cui J; Shadick N
JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
[No Abstract] [Full Text] [Related]
[Next] [New Search]